Septerna (NASDAQ:SEPN) Given New $11.00 Price Target at Wells Fargo & Company

Septerna (NASDAQ:SEPN) had its price objective decreased by Wells Fargo & Company from $14.00 to $11.00 in a report issued on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Septerna Stock Down 3.0 %

NASDAQ SEPN opened at $6.10 on Friday. The firm has a 50-day simple moving average of $9.96. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million. On average, research analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Insider Buying and Selling

In other Septerna news, Director Alan Ezekowitz bought 41,355 shares of the stock in a transaction on Thursday, March 6th. The stock was purchased at an average price of $6.00 per share, with a total value of $248,130.00. Following the completion of the purchase, the director now owns 104,101 shares in the company, valued at $624,606. The trade was a 65.91 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Gil M. Labrucherie bought 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was bought at an average cost of $5.85 per share, with a total value of $29,250.00. Following the acquisition, the chief financial officer now directly owns 30,000 shares of the company’s stock, valued at approximately $175,500. The trade was a 20.00 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 74,346 shares of company stock worth $439,670.

Hedge Funds Weigh In On Septerna

A number of institutional investors have recently added to or reduced their stakes in SEPN. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Septerna in the fourth quarter valued at approximately $2,353,000. Woodline Partners LP acquired a new stake in shares of Septerna during the 4th quarter valued at $6,870,000. Zimmer Partners LP bought a new stake in Septerna during the 4th quarter worth $229,000. Soleus Capital Management L.P. acquired a new position in Septerna in the 4th quarter worth about $15,467,000. Finally, Nuveen Asset Management LLC bought a new position in Septerna in the fourth quarter valued at about $549,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.